PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
29.77%
Net income growth above 1.5x RVPH's 14.29%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-0.50%
Negative yoy D&A while RVPH is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
15.92%
Deferred tax of 15.92% while RVPH is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
0.65%
Less SBC growth vs. RVPH's 11.47%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-31.26%
Both reduce yoy usage, with RVPH at -89.42%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.84%
A yoy AP increase while RVPH is negative at -154.34%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-40.45%
Both reduce yoy usage, with RVPH at -15.99%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-15.92%
Negative yoy while RVPH is 52.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
32.67%
Some CFO growth while RVPH is negative at -43.65%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
CapEx growth of 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-58.30%
Negative yoy issuance while RVPH is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.